New aspects of allergic rhinitis treatment

Cover Page

Cite item

Full Text

Abstract

Allergic rhinitis is a worldwide disease, which occurred from 17% to 40% of the population in different countries. Allergic rhinitis affects negative on the quality of patient’s life and is often associated with asthma. Modern strategy for the treatment of allergic rhinitis based on three principles: the elimination of contact with the allergic agent, pharmacotherapy and immunotherapy. The second generation of the antihistamines drugs, as a representative of pharmacotherapy, are used at all stages of the allergic rhinitis treatment due to their high therapeutic efficacy and have not only anti-allergic, but also anti-inflammatory effect. In this article provides a comparative review of the effectiveness of second-generation antihistamines drugs among themselves and in comparison with antileukotriene medications. Although the availability of effective drugs for allergic rhinitis treatment, there is some kind of patients who had no effect from drugs. At the recent time, there are some searches for a new drugs and / or delivery methods for “known” drugs that would improve allergic rhinitis treatment. At first sight, intranasal using of drugs combines a good safety with high efficiency. However, after determining the molecular goal, one drug can affect a greater number of diseases or symptoms. From this point of view, it is preferable to use one systemic drug for stopping the variations of an allergic reaction.

About the authors

Sergei A. Karpishchenko

Pavlov First Saint Petersburg State Medical University

Email: karpischenkos@mail.ru
D. Sci. (Med.), Full Prof. Saint Petersburg, Russia

Olga M. Kolesnikova

Pavlov First Saint Petersburg State Medical University

Email: olga_lozo@mail.ru
Cand. Sci. (Med.), Assoc. Prof. Saint Petersburg, Russia

References

  1. Brożek J.L, Bousquet J, Agache I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol 2017; 140 (4): 950-8.
  2. http: //www.whogis.com/gho/ru/
  3. Compalati E, Ridolo E, Passalacqua G et al. The link between allergic rhinitis and asthma: the united airways disease. Expert Rev Clin Immunol 2010; 6 (3): 413-23.
  4. Baiardini I, Braido F, Tarantini F et al. ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review. Allergy 2008; 63 (6): 660-9.
  5. Антонов В.Б., Медведева Т.В., Соболев А.В. Микогенные аллергии. Аллергология. 1998; 2: 23-6.
  6. Карпищенко С.А., Рябова М.А., Лаврова О.В. и др. К вопросу о дифференциальной диагностике воспалительной патологии верхних дыхательных путей у беременных. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2017; 23 (2): 20-2.
  7. Canonica G, Triggiani M, Senna G. Clin Mol Allergy 2015; 13: 25. doi: 10.1186/s12948-015-0029-5
  8. Белан Э.Б., Садчикова Т.Л. Аллергический ринит: современные подходы к диагностике и лечению. Лекарственный вестн. 2017; 3 (67). Т. 11: 3-11.
  9. Bousquet J, Dahl R, Khaltaev N. GARD (Global alliance against chronic respiratory diseases). Rev Maladies Respiratoires 2006; 23 (4): 73-5. doi: 10.1111/j.1398-9995.2008.01640.x
  10. Pawankar R. Allergic diseases and asthma: A global public health concern and a call to action. World Allergy Organization J 2014; 7 (1): 12. doi: 10.1186/1939-4551-7-12
  11. Thomas S.H.L. Antihistamine poisoning. Medicine 2012; 40: 109-10.
  12. Tran N.P, Vickery J, Blaiss M.S. Management of Rhinitis: Allergic and Non-Allergic. Allergy, Asthma Immunol Res 2011; 3 (3): 148. doi: 10.4168/aair.2011.3.3.148
  13. Grant J.A, Danielson L, Rihoux J.P, DeVos C. A double-blind single dose, crossover comparison of cetirizine, ebastine, epinestine, fexofenadine, terfenadine and loratadine versus placebo: suppression of histamineinduced wheal and flare response for 24 h in healthy male subjects. Allergy 1999; 54: 700-7.
  14. Gispert J, Antonijoan R, Barbanoj M et al. Efficacy of ebastine, cetirizine, and loratadine in histamine cutaneous challenge. Ann Allergy Asthma Immunol 2002; 89: 259-64.
  15. Moss A.J, Chaikin P, Garcia J.D et al. A review of the cardiac systemic side-effects of antihistamines: ebastine. Clin Exp Allergy 1999; 29 (Suppl. 3): 200-5.
  16. Gillen M.S, Miller B, Chaikin P, Morganroth J. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br J Clin Pharmacol 2001; 52: 201-4.
  17. Pecoraro L, Paiola G, Pietrobelli A. Ebastine overdose in a child. Clin Case Rep 2017; 5 (4): 403-5. doi: 10.1002/ccr3.845
  18. Heffler E, Brussino L, Giacco S. New drugs in early-stage clinical trials for allergic rhinitis Expert Opin Investig Drugs 2019; 28 (3): 267-73. doi: 10.1080/13543784.2019.1571581
  19. Hamed A, Preston D, Eschenbacher W. Nasal IgE Production in Allergic Rhinitis: Impact of Rhinovirus Infection Clin Exp Allergy. 2019. doi: 10.1111/cea.13372
  20. Seidman M.D, Gurgel R.K, Lin S.Y et al. Guideline Otolaryngology Development Group, Clinical practice guideline: allergic rhinitis, Otolaryngol. Head Neck Surg 2015; 152: S1-43.
  21. Wei C. The efficacy and safety of H1-antihistamine versus Montelukast for allergic rhinitis: A systematic review and meta-analysis. Biomed Pharmacother 2016; 83: 989-97.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).